T-cell–based immunotherapies can be effective in the treatment of large vascularized
tumors, but they rely on adoptive transfer of substantial numbers (∼ 20 million) of tumor …

Adoptive cell therapy with tumor-targeted T cells is a promising approach to cancer therapy.
Enhanced clinical outcome using this approach requires conditioning regimens with total …

Solid tumors are complex masses with a local microenvironment, or stroma, that supports
tumor growth and progression. Among the diverse tumor-supporting stromal cells is a …

Engineering CD8+ T cells to deliver interleukin 12 (IL-12) to the tumor site can lead to
striking improvements in the ability of adoptively transferred T cells to induce the regression …

Adoptive therapy with engineered T cells shows promising results in treating patients with
malignant disease, but is challenged by incomplete responses and tumor recurrences. Here …

It is a challenge to effectively reactivate preexisting tumor-infiltrating lymphocytes (TILs)
without causing severe toxicity. Interleukin-12 (IL-12) can potently activate lymphocytes, but …

Because cytokine-priming signals direct CD8+ T cells to acquire unique profiles that affect
their ability to mediate specific immune responses, here we generated IL-9–skewed CD8+ T …

During malignant progression cancer cells tend to lose cell surface expression of MHC and
other immune antigens, making them invisible to cytotoxic T cells and therefore inaccessible …

Interleukin-12 (IL-12) is an important immunostimulatory cytokine, yet its clinical application
has been limited by the systemic toxicity associated with its administration. In this work, we …

Summary Interleukin-12 (IL-12) gene transfer enhances the therapeutic potency of adoptive
T cell therapies. We previously reported that transient engineering of tumor-specific CD8 T …